

COVAX Portfolio Briefing to the Gavi Board

June 25, 2020

Richard Hatchett, MD
CEO, Coalition for Epidemic Preparedness Innovation





Our mission

CEPI accelerates development of vaccines against emerging infectious diseases and enables equitable access to these vaccines for affected populations during outbreaks

Speed requires a paradigm shift


Traditional paradigm
5 – 10+ years*



Outbreak paradigm
12 – 18 months



Clinical Development



Manufacturing Scale up/out



CEPI's vaccine development so far...

- CEPI has launched more than 20 programs in 3.5 years for 5 target pathogens, including 3 rapid response platforms.
- CEPI's COVID-19 portfolio includes 9 vaccines, with more to follow.
 - Rapid response vaccines were engaged in January 2020
 - First CEPI-supported vaccine initiated clinical trials March 16, 2020
 - Six projects now testing vaccine response in human subjects
 - Remaining programs will enter clinical trials later in coming months.

Current CEPI COVID-19 vaccine portfolio consists of 9 projects


COVID-19



	Inovio	University of Queensland / CSL	CureVac	Moderna	Clover BioPharma	Merck / Themis	Novavax	University of Hong Kong	AZ / Univ. Oxford
Location	USA	Australia	Germany	USA	China	USA/Austria	USA	China	UK
Platform	DNA	Protein	RNA	mRNA	Protein	Viral Vector	Protein	Viral Vector	Viral Vector
Antigen / Adjuvant	Full-length S protein	Full-length S protein / MF59 or AS03 or CPG1018	Full-length S protein	Full-length S protein	Full-length S protein / AS03 or CPG1018	Full-length S protein	Full-length S protein / saponin-based Matrix-M	Receptor Binding Domain / AS03	Full-length S protein
Current phase	Phase 1	Preclinical	Preclinical	Phase I/IIa	Preclinical	Preclinical	Phase I	Preclinical	Phase I/II



Speed



Scale



Access


Covid-19 vaccine clinical development pipeline

■ Shading denotes CEPI-funded

Date: 22 June 2020

Candidate	Vaccine characteristics	FIH / FPI Start date	Current stage (most advanced)	#Sites/Location	Lead Partner
ChAdOx1 nCoV-19	ChAdOx1 vector that expresses S protein	TBU	Phase II/III (NCT04400838)	10260 sub. in 20 sites / UK	AstraZeneca / Oxford
Ad5-nCoV	Adenovirus type 5 vector that expresses S protein	01 Apr 20	Phase II (NCT04341389)	500 sub. in ? sites / China	Cansino
mRNA-1273	LNP-encapsulated mRNA vaccine encoding S protein	01 Jun 20	Phase II (NCT04405076)	600 sub. in 10 sites / USA	Moderna Therapeutics
SARS-CoV-2 inactivated	Inactivated Novel Coronavirus Pneumonia vaccine (Vero cells)	11 Apr 20	Phase I/II (ChiCTR2000031809)	1376 sub. in ? sites / China	Wuhan Institute of biological products
SARS-CoV-2 inactivated	Inactivated novel coronavirus (2019-CoV) vaccine (Vero cells)	29 Apr 20	Phase I/II (ChiCTR2000032459)	2128 sub. in 1 site / China	Beijing Institute of Biotechnology
Inactivated Virus	SARS-CoV-2 inactivated vaccine	16 Apr 20	Phase I/II (NCT04352608)	744 sub. in 1 site / China	Sinovac Biotech
Inactivated Virus	SARS-CoV-2 inactivated vaccine	15 May 20	Phase I/II (NCT04412538)	942 sub. in 1 sites / China	IMB, Chinese Academy of Medical Sciences
LV-SMENP-DC	DCs modified with LV vector expressing synthetic minigene based on domains of selected viral proteins; administered with antigen-specific CTLs	24 Mar 20	Phase I/II (NCT04276896)	100 sub. in 3 sites / China	Shenzhen GIMI
mRNA-BNT162	mRNA NRM / SAM constructs with LNP	05 May 20	Phase I/II (NCT04368728)	200 sub. in 1 site / Germany 7600 sub. in 5 sites / US	Pfizer; BioNTech
NVX-CoV2373	stable, prefusion protein, includes Matrix-M™ adjuvant	25 May 20	Phase I/II (NCT04368988)	136 sub. in 2 sites / Australia	Novavax
saRNA	self-amplifying RNA	19 Jun 20	Phase I/II	UK	Imperial
Pathogen-specific aAPC	aAPCs modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins	TBU	Phase I (NCT04299724)	100 sub. in 1 site / China	Shenzhen GIMI
INO-4800	DNA plasmid encoding S protein delivered by electroporation	06 Apr 20	Phase I (NCT04336410)	40 sub. in 2 sites / USA	Inovio Pharmaceuticals
SCB-2019	a Recombinant SARS-CoV-2 Trimeric S Protein Subunit Vaccine	19 Jun 20	Phase I (NCT04405908)	150 sub in ? Sites / Australia	Clover Biopharmaceuticals
CVnCoV	mRNA encodes the spike protein of SARS-CoV-2 and is made up of lipid nanoparticles (LNP)	19 Jun 20	Phase I	Germany; Belgium	CureVac

Building Capacity at Risk – Multiple products



Thank You

